Objective: HER2 in gastric cancer (GC) should be assessed following guidelines -recommended testing algorithm employs IHC as a screening tool and is followed by ISH to clarify equivocal cases. Reported incidences of HER2+ GC vary substantially and discordant results are frequent. In a series of GC HER2 was assessed by IHC and FISH to determine incidence of HER2+ GC, concordance of the methods and reevaluate the recommended algorithm.